Early proof-of-concept studies presented today show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments.Findings from a Phase II study show that RAD001 enhances tumour shrinkage when given in combination with letrozole (Femara®) to postmenopausal women with newly diagnosed oestrogen receptor-positive (ER+) breast cancer.
More...